Business Context and Reporting Period
This Form 6-K filing, dated September 19, 2013, reports on a financing event for Celsus Therapeutics PLC (note: the request metadata lists "Akari Therapeutics Plc," but the filing text explicitly identifies the registrant as Celsus Therapeutics PLC). The document details a private placement of ordinary shares entered into on September 19, 2013, with a closing expected on or about September 24, 2013.
Key Financial Metrics
- Capital Raised: $12,516,232 aggregate purchase price.
- Shares Issued: 21,958,302 ordinary shares sold to institutional accredited investors.
- Additional Issuances: 4,046,692 additional shares to be issued to previous investors due to price protection provisions; 1,259,092 shares issuable upon exercise of outstanding warrants.
- Management Participation: CEO Gur Roshwalb purchased 87,719 shares for $50,000.
- Placement Agents: MTS Health Partners, L.P. and Oppenheimer & Co.
Material Changes
The filing does not provide comparative financial data (revenue, profit, or cash flow) against prior periods. The primary material change is the significant increase in share count and equity capital resulting from the private placement and associated price protection adjustments.
Guidance, Outlook, and Risks
Registration Rights: The Company agreed to file a registration statement for the resale of shares within 30 days of closing and have it declared effective within 60 days (or 120 days if reviewed by the SEC).
Penalties for Delay: If the registration statement is not filed or declared effective by the deadlines, the Company must pay investors 1.5% of their original investment amount on the date of failure and every 30-day anniversary thereafter. Late payments accrue interest at 1.0% per month.
Unusual Items: The transaction includes significant dilution mechanisms (price protection shares and warrant exercises) triggered by this offering.
Investor Verification Checklist
- Verify the exact closing date and confirmation of funds received (expected ~September 24, 2013).
- Confirm the total post-offering share count including the 4,046,692 price protection shares and 1,259,092 warrant shares.
- Monitor the filing and effectiveness of the registration statement to avoid the 1.5% penalty payments.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.